Sellas Life Sciences Group(NASDAQ) SLS

SELLAS Life Sciences Group, Inc. makes new cancer medicines. These medicines help the body find and kill tumor cells. They help patients fighting blood and solid tumor cancers.

Key Treatments in Development

• Galinpepimut-S (GPS): Immunotherapy targeting the Wilms tumor 1 (WT1) protein, which acts as a marker found in more than 20 cancer types.
• SLS009 (tambiciclib): Selective inhibitor of the CDK9 protein, which helps cancer cells grow, designed to reduce toxicity compared to older treatments.
• Clinical Combinations: Research testing company drugs alongside other treatments to attack blood cancers and solid tumors.

Clinical Milestones and Strategic Alliances

• Completed enrollment for the Phase 3 REGAL clinical trial in March 2024.
• Entered an exclusive license agreement with GenFleet Therapeutics in March 2022 for worldwide rights to SLS009.
• Partnered with the IMPACT-AML network in January 2026 to conduct clinical studies and expand European patient access.
• Received Rare Pediatric Disease designation from the FDA for GPS to treat pediatric acute myeloid leukemia, a type of blood cancer, in October 2024.

What Makes Sellas Different?

Sellas holds multiple regulatory designations, such as Orphan Drug and Fast Track status, which provide incentives for developing treatments for rare diseases. The company also focuses on maintenance therapy, which aims to keep patients in remission after their initial cancer treatment ends.

A Look at the Numbers

• Net loss was $18.0 million for the six months ended June 30, 2026.
• Cash and cash equivalents totaled $138.3 million as of June 30, 2026.
• Research and development expenses were $11.4 million for the six months ended June 30, 2026, compared to $7.1 million for the six months ended June 30, 2025.
• Manufacturing costs grew by $2.3 million for the six months ended June 30, 2026, to prepare for potential drug approval filings.
• Financing activities provided $82.9 million in net cash during the six months ended June 30, 2026.

Bottom Line

Sellas has progressed from early research to late-stage clinical testing of its primary cancer therapies. International partnerships and significant cash reserves support the company's efforts to reach regulatory approval and commercial use for its drug candidates.